Metformina + Linagliptina Mylan

Metformin hydrochloride, the active ingredient in Metformina + Linagliptina Mylan, is a biguanide combined with linagliptin, a DPP‑4 inhibitor, presented as an oral tablet for the management of type 2 diabetes mellitus in adult patients. The fixed‑dose combination improves glycemic control by decreasing hepatic glucose output and enhancing incretin‑mediated insulin secretion.

GNH USA supplies Metformina + Linagliptina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance globally.

Metformina + Linagliptina is indicated for type 2 diabetes mellitus, targeting hyperglycemia through combined biguanide and DPP‑4 inhibition.

- Type 2 diabetes mellitus (monotherapy): improves fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combined therapy): enhances glycemic control when added to other antidiabetic agents. - Type 2 diabetes mellitus (adjunct to diet and exercise): supports lifestyle measures to achieve target HbA1c.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset often occurring early in therapy. - Diarrhea: loose stools that may resolve with continued use. - Abdominal discomfort: cramping or pain in the stomach area. - Headache: transient head pain without other neurological signs. - Metallic taste: altered taste perception in the mouth. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: a life‑threatening buildup of lactate, especially in renal impairment. - Severe hypoglycemia: marked low blood glucose, usually when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Acute renal failure: sudden loss of kidney function. - Hepatic dysfunction: abnormal liver enzyme elevations. - Anaphylactic reaction: severe allergic response with rash, swelling, or breathing difficulty.

Before initiating therapy, several safety considerations should be reviewed.

- Renal function assessment: evaluate creatinine clearance to avoid accumulation. - Hepatic disease monitoring: use cautiously in patients with liver impairment. - Risk of lactic acidosis: contraindicated in severe renal or hepatic failure. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Elderly patients: start at lower dose and monitor for renal function. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Metformina + Linagliptina may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure when combined with metformin. - Concurrent use of other DPP‑4 inhibitors: may increase risk of adverse effects without added benefit. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may enhance metformin‑related hypoglycemia. - Corticosteroids: can increase blood glucose, requiring dose adjustments. - Beta‑blockers: may mask hypoglycemia symptoms. - Cimetidine: may reduce renal clearance of metformin.